Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Hanna Roberts to Hemophilia B

This is a "connection" page, showing publications Hanna Roberts has written about Hemophilia B.

 
Connection Strength
 
 
 
0.653
 
  1. Chang JY, Monroe DM, Stafford DW, Brinkhous KM, Roberts HR. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest. 1997 Aug 15; 100(4):886-92.
    View in: PubMed
    Score: 0.139
  2. Monroe DM, Hoffman M, Roberts HR, Hedner U. Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia. 2013 Nov; 19(6):926-32.
    View in: PubMed
    Score: 0.105
  3. Monroe DM, McCord DM, Huang MN, High KA, Lundblad RL, Kasper CK, Roberts HR. Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood. 1989 May 01; 73(6):1540-4.
    View in: PubMed
    Score: 0.078
  4. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost. 2007 Aug; 5(8):1577-83.
    View in: PubMed
    Score: 0.069
  5. McGraw RA, Davis LM, Lundblad RL, Stafford DW, Roberts HR. Structure and function of factor IX: defects in haemophilia B. Clin Haematol. 1985 Jun; 14(2):359-83.
    View in: PubMed
    Score: 0.060
  6. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998 Nov; 4(6):790-8.
    View in: PubMed
    Score: 0.038
  7. Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost. 1997 May; 77(5):944-8.
    View in: PubMed
    Score: 0.034
  8. Lefkowitz JB, Monroe DM, Kasper CK, Roberts HR. Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. Am J Hematol. 1993 Jul; 43(3):177-82.
    View in: PubMed
    Score: 0.026
  9. Brown PE, Hougie C, Roberts HR. The genetic heterogeneity of hemophilia B. N Engl J Med. 1970 Jul 09; 283(2):61-4.
    View in: PubMed
    Score: 0.021
  10. Lozier JN, Monroe DM, Stanfield-Oakley S, Lin SW, Smith KJ, Roberts HR, High KA. Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood. 1990 Mar 01; 75(5):1097-104.
    View in: PubMed
    Score: 0.021
  11. Huang MN, Kasper CK, Roberts HR, Stafford DW, High KA. Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. Blood. 1989 Feb 15; 73(3):718-21.
    View in: PubMed
    Score: 0.019
  12. Braunstein KM, Noyes CM, Griffith MJ, Lundblad RL, Roberts HR. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. J Clin Invest. 1981 Dec; 68(6):1420-6.
    View in: PubMed
    Score: 0.012
  13. Johnson CA, Chung KS, McGrath KM, Bean PE, Roberts HR. Characterization of a variant prothrombin in a patient congenitally deficient in factors II, VII, IX and X. Br J Haematol. 1980 Mar; 44(3):461-9.
    View in: PubMed
    Score: 0.010
  14. Chung KS, Goldsmith JC, Roberts HR. Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX. Bibl Haematol. 1977; 44:68-74.
    View in: PubMed
    Score: 0.008
  15. Pike IM, Yount WJ, Puritz EM, Roberts HR. Immunochemical characterization of a monoclonal G4,lambda human antibody to factor IX. Blood. 1972 Jul; 40(1):1-10.
    View in: PubMed
    Score: 0.006
  16. McLester WD, Roberts HR, Wagner RH. Use of an immunosorbent technique in the study of a PTC inhibitor: a new method for the investigation of blood coagulation. J Lab Clin Med. 1965 Oct; 66(4):682-7.
    View in: PubMed
    Score: 0.004
  17. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A. 1983 Jul; 80(14):4200-2.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)